Compugen Limited

Compugen Limited

Compugen Limited is a clinical-stage biotechnology company focused on drug discovery and development, leveraging its predictive computational discovery platform to identify novel drug targets and biological pathways for cancer immunotherapies. The firm, with offices in Holon, Israel, and Toronto and Ottawa, Canada, operates at the intersection of computational biology and immuno-oncology. Compugen's pipeline centers on its Unigen™ platform, which drives the discovery of new drug targets and the development of therapeutic antibodies. The company is advancing multiple clinical trials evaluating potentially first-in-class antibodies targeting novel pathways, designed to extend the reach of immunotherapies. Key programs include investigational compounds targeting PVRIG and TIGIT pathways, with partnerships like a 2020 collaboration with Bristol Myers Squibb for COM-701 and COM-902. The geographic footprint spans Israel and Canada, reflecting R&D operations in both regions. The firm's scale is modest relative to large pharma, but its computational approach differentiates it in target discovery. No recent financing or material operational event has been publicly disclosed in the last 24 months. Adjacent activities include corporate presentations and recruitment of research experts and drug developers. What structurally distinguishes Compugen is its reliance on a proprietary computational platform for target discovery, rather than traditional high-throughput screening. This in-silico pipeline allows identification of targets not easily found by other methods, potentially reducing the time and cost of early-stage drug development.